Vericel (VCEL) entered into a 2-year renewable agreement with Orsini Pharmaceutical for distribution of Carticel® and MACI® in the U.S. and Puerto Rico. Orsini will work with Vericel’s service provider, Pro-Spectus, for management of patient cases related to the products.
Concurrently, VCEL announced the pending June 2017 termination of an agreement with Dohmen Life Science Services. As reported with its 2Q16 revenue results, VCEL had entered into collaboration with Dohmen to provide patient support and payor contracting/product reimbursement for Carticel and MACI under a fee-per-service structure.
Sources: Form 8-K for Vericel Corporation, SEC.gov; ORTHOWORLD Inc.